title: Achieving cholesterol goals. Current and future drug therapies.
abstract: Low-density lipoprotein cholesterol (LDL-C), the prime target of antilipidemic therapy, should be lowered to below 100 mg/dL for patients with coronary heart disease (CHD) and CHD risk equivalents, including diabetes, noncoronary atherosclerotic disorders, and multiple risk factors and a 10-year CHD risk greater than 20%. Five 3-hydroxy-3- methylglutaryl-CoenzymeA reductase inhibitors ("statins") are approved for use in the United States. A sixth, rosuvastatin, is awaiting approval. Of all the statins, rosuvastatin provides the greatest reductions in LDL-C along with the greatest increases in high-density lipoprotein cholesterol. The statins can be used alone, or in combination with a bile acid sequestrant, ezetimibe, or niacin in patients with mixed dyslipidemias.
authors: Baylor College of Medicine, Houston, TX 77030, USA. jones@bcm.tmc.edu
authors: Peter H
authors: PH
authors: Jones
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001384:Azetidines / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000517:prevention & control*; D050171:Dyslipidemias / Q000188:drug therapy; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009525:Niacin / Q000008:administration & dosage
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin; D000069438:Ezetimibe